6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-19), Vertex Pharmaceuticals's 6-1 Month Momentum % is 13.82%.
The industry rank for Vertex Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:
VRTX's 6-1 Month Momentum % is ranked better than 62.54% of 1519
companies
in the Biotechnology industry
Industry Median: -1.21
vs VRTX: 13.82
Competitive Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals 6-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vertex Pharmaceuticals 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals (Vertex Pharmaceuticals) Business Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VRTX has been successfully added to your